Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice

被引:94
|
作者
Dash, Prasanta K. [1 ,4 ]
Gendelman, Howard E. [1 ,4 ]
Roy, Upal [1 ,4 ]
Balkundi, Shantanu [1 ,4 ]
Alnouti, Yazen [2 ]
Mosley, Rodney L. [1 ,4 ]
Gelbard, Harris A. [3 ]
McMillan, JoEllyn [1 ,4 ]
Gorantla, Santhi [1 ,4 ]
Poluektova, Larisa Y. [1 ,4 ]
机构
[1] Univ Nebraska Med Ctr, Coll Med, Ctr Neurodegenerat Disorders, Omaha, NE USA
[2] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE USA
[3] Univ Rochester, Sch Med & Dent, Dept Neurol, Ctr Neural Dev & Dis,Child Neurol Div, Rochester, NY 14642 USA
[4] Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE USA
基金
美国国家卫生研究院;
关键词
central nervous system; drug biodistribution; HIV-associated neurocognitive disorders; humanized mice; HIV-1; nanoformulated antiretroviral therapy; PROGRESSIVE HIV-1 INFECTION; ATAZANAVIR-RITONAVIR; DRUG-DELIVERY; REGIMEN SIMPLIFICATION; MOUSE; MODEL; PHARMACOKINETICS; MACROPHAGES; SUPPRESSION; LIMITATIONS;
D O I
10.1097/QAD.0b013e328357f5ad
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: Long-acting nanoformulated antiretroviral therapy (nanoART) with improved pharmacokinetics, biodistribution and limited systemic toxicities will likely improve drug adherence and access to viral reservoirs. Design: Atazanavir and ritonavir crystalline nanoART were formulated in a poloxamer-188 excipient by high-pressure homogenization. These formulations were evaluated for antiretroviral and neuroprotective activities in humanized NOD/scid-IL-2Rg(c)(null) (NSG) mice. Methods: NanoART-treated NSG mice were evaluated for drug biodistribution, pharmacodynamics and toxicity. CD34(+) human hematopoietic stem cells were transplanted at birth in replicate NSG mice. The mice were infected with HIV-1(ADA) at 5 months of age. Eight weeks later, the infected animals were treated with weekly subcutaneous injections of nanoformulated ATV and RTV. Peripheral viral load, CD4(+) T-cell counts and lymphoid and brain histopathology and immunohistochemistry tests were performed. Results: NanoART treatments by once-a-week injections reduced viral loads more than 1000-fold and protected CD4(+) T-cell populations. This paralleled high ART levels in liver, spleen and blood that were in or around the human minimal effective dose concentration without notable toxicities. Importantly, examination of infected brain subregions showed that nanoART elicited neuroprotective responses with detectable increases in microtubule-associated protein-2, synaptophysin and neurofilament expression when compared to untreated virus-infected animals. Therapeutic interruptions produced profound viral rebounds. Conclusion: Long-acting nanoART has translational potential with sustained and targeted efficacy and with limited systemic toxicities. Such success in drug delivery and distribution could improve drug adherence and reduce viral resistance in infected people. (c) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
下载
收藏
页码:2135 / 2144
页数:10
相关论文
共 50 条
  • [1] Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients
    Williams, Jennifer
    Sayles, Harlan R.
    Meza, Jane L.
    Sayre, Patrick
    Sandkovsky, Uriel
    Gendelman, Howard E.
    Flexner, Charles
    Swindells, Susan
    NANOMEDICINE, 2013, 8 (11) : 1807 - 1813
  • [2] Long-acting nanoformulated anti-retroviral drugs are neuroprotective in HIV-1 infected humanized mice brains
    Dash, Prasanta
    Gorantla, Santhi
    Roy, Upal
    Balkundi, Shantanu
    Knibbe, Jaclyn
    McMillan, JoEllyn
    Gelbard, Harris
    Poluektova, Larisa
    Gendelman, Howard
    JOURNAL OF NEUROVIROLOGY, 2012, 18 : 29 - 29
  • [3] Cell-Targeted Long-Acting Nanoformulated Antiretroviral Therapy
    Puligujja, Pavan
    Veerubhotla, Ram
    McMillan, JoEllyn
    Gendelman, Howard
    Liu, Xinming
    JOURNAL OF NEUROVIROLOGY, 2012, 18 : 88 - 88
  • [4] Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy
    Gautam, Nagsen
    Roy, Upal
    Balkundi, Shantanu
    Puligujja, Pavan
    Guo, Dongwei
    Smith, Nathan
    Liu, Xin-Ming
    Lamberty, Benjamin
    Morsey, Brenda
    Fox, Howard S.
    McMillan, JoEllyn
    Gendelman, Howard E.
    Alnouti, Yazen
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (07) : 3110 - 3120
  • [5] Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages
    Arainga, Mariluz
    Guo, Dongwei
    Wiederin, Jayme
    Ciborowski, Pawel
    McMillan, JoEllyn
    Gendelman, Howard E.
    RETROVIROLOGY, 2015, 12
  • [6] Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages
    Mariluz Araínga
    Dongwei Guo
    Jayme Wiederin
    Pawel Ciborowski
    JoEllyn McMillan
    Howard E Gendelman
    Retrovirology, 12
  • [7] Long-Acting, Potent Delivery of Combination Antiretroviral Therapy
    Andersen, Anna H. F.
    Riber, Camilla F.
    Zuwala, Kaja
    Tolstrup, Martin
    Dagnaes-Hansen, Frederik
    Denton, Paul W.
    Zelikin, Alexander N.
    ACS MACRO LETTERS, 2018, 7 (05): : 587 - 591
  • [8] Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for NeuroAIDS Therapeutics
    Nowacek, Ari S.
    McMillan, JoEllyn
    Miller, Reagan
    Anderson, Alec
    Rabinow, Barrett
    Gendelman, Howard E.
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2010, 5 (04) : 592 - 601
  • [9] Long-acting antiretroviral therapy
    Soriano, Vicente
    Barreiro, Pablo
    de Mendoza, Carmen
    NATURE MATERIALS, 2020, 19 (08) : 826 - 827
  • [10] Long-acting antiretroviral therapy
    Vicente Soriano
    Pablo Barreiro
    Carmen de Mendoza
    Nature Materials, 2020, 19 : 826 - 827